Open letters to Otsuka, Janssen Pharmaceutical Companies of Johnson & Johnson, Food and Drug Administration and European Medicines Agency.

Medical innovation is not delivering for the needs of people in developing countries. 65th World Health Assembly to debate binding convention on R&D.

Tuberculosis is still one of the most important causes of death worldwide. Perseverance and renewed commitment are needed to achieve global control of tuberculosis, and ultimately, its elimination.

As of the end of the first quarter of 2012, nearly 864,000 GeneXpert MTB/RIF rapid tuberculosis (TB) diagnostic cartridges had been procured under manufacturer Cephied’s concessional pricing mechanism.

Between 1990 and 2010, in countries with tuberculosis (TB) programs supported by USAID, TB death rates decreased by 29 percent, and TB prevalence rates declined by 14 percent.

Through spearheading innovative initiatives and providing financing for global health over the past five years, UNITAID has had a dramatic impact on millions of lives, using creative market approaches to increase access to treatment and diagnostics for HIV, malaria and tuberculosis.

Response by Medicines Control Council to letter by Global TB CAB on bedaquiline.

Research released by the Copenhagen Consensus Center identifies TB as a key priority for infectious disease control in terms of cost effectiveness and disease burden.

Open letter regarding Cepheid pricing of the GeneXpert machines and cartridges for high-burden settings in the public and private sectors.

Open letter to the Medicines Control Council of South Africa regarding compassionate use of bedaquiline for drug-resistant tuberculosis in South Africa.